Controversies on individualized prostate cancer care: gaps in current practice.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 3763777)

Published in Ther Adv Urol on October 01, 2013

Authors

Steven Joniau1, David Pfister, Alexandre de la Taille, Franco Gaboardi, Alan Thompson, Maria J Ribal

Author Affiliations

1: University Hospitals Leuven, Leuven, Belgium.

Articles citing this

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res (2015) 0.78

Articles cited by this

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Osteoclast differentiation and activation. Nature (2003) 18.59

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93

Natural history of early, localized prostate cancer. JAMA (2004) 7.44

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain (1995) 5.97

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09

Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01

Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol (2008) 3.34

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol (2010) 2.82

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol (2008) 2.65

Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol (2011) 2.63

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol (2012) 2.42

Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol (2005) 2.41

Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst (2001) 2.09

Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol (2011) 1.91

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging (2010) 1.85

The prostate cancer pseudo-epidemic. Acta Oncol (2010) 1.67

Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol (2010) 1.60

Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol (2011) 1.58

A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int (2012) 1.57

The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst (1996) 1.52

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis (2011) 1.50

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol (2006) 1.49

The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res (2006) 1.35

Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer (2005) 1.33

Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26

Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology (2008) 1.26

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20

Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2002) 1.15

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol (2012) 1.14

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res (2010) 1.09

Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments. Ann Surg Oncol (2011) 1.07

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int (2010) 1.06

A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis (2007) 1.06

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging (2011) 1.06

Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol (2006) 1.03

Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006. Br J Cancer (2009) 1.01

Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int (2007) 1.00

Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score. Spine (Phila Pa 1976) (2012) 1.00

The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99

Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy. BJU Int (2011) 0.99

Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw (2010) 0.97

Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology (2008) 0.97

Men's perspectives on selecting their prostate cancer treatment. J Natl Med Assoc (2011) 0.96

Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int (2010) 0.89

MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging (2012) 0.88

The role of lymph node dissection in the management of prostate cancer. Int J Clin Oncol (2011) 0.86

Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int (2010) 0.86

Medical and non-medical determinants of prostate cancer management: a population-based study. Eur J Cancer (2003) 0.86

Management of early prostatic cancer in the Nordic countries: variations in clinical policies and physicians' attitudes toward radical treatment options. Int J Technol Assess Health Care (1995) 0.85

Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance. Urol Int (2012) 0.85

Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res (2008) 0.83

Mapping the psychosocial and practical support needs of cancer patients in Western Australia. Eur J Cancer Care (Engl) (2011) 0.82

Contemporary role of radiation therapy in the adjuvant or salvage setting following radical prostatectomy. Curr Opin Urol (2011) 0.81

Prognostic significance of global grading system of Gleason score in patients with prostate cancer with bone metastasis. BJU Int (2009) 0.81

Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81

Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol (2002) 0.81

Prostate cancer: the benefits of multidisciplinary prostate cancer care. Nat Rev Urol (2012) 0.80

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology (2008) 0.80

Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol (2005) 0.77

Prostate-specific antigen and prostate cancer prognosis. J Natl Cancer Inst (2006) 0.76

PCA: prostate cancer, patient-centred approach or both? BJU Int (2012) 0.76

Articles by these authors

(truncated to the top 100)

Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27

Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94

Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92

Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol (2009) 2.40

Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37

Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol (2008) 2.34

Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26

Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol (2008) 2.25

The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr (2009) 2.16

Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15

Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol (2008) 2.13

Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10

Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2005) 2.04

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03

Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. Eur Urol (2006) 1.95

Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91

Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88

Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77

Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? J Urol (2009) 1.73

Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69

Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68

Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63

Modified supine percutaneous nephrolithotomy for large kidney and ureteral stones: technique and results. Eur Urol (2011) 1.58

Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature. Eur Urol (2012) 1.57

Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy. BJU Int (2011) 1.56

Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn (2007) 1.55

The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53

Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol (2011) 1.52

Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.52

Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51

The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol (2011) 1.50

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate (2011) 1.49

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45

Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42

International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41

Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol (2012) 1.40

Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40

Surgical management of BPH in patients on oral anticoagulation: transurethral bipolar plasma vaporization in saline versus transurethral monopolar resection of the prostate. Can J Urol (2011) 1.38

Helicobacter pylori in First Nations and recent immigrant populations in Canada. Can J Gastroenterol (2012) 1.38

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36

Surgical resection of urological tumor metastases following medical treatment. Dtsch Arztebl Int (2012) 1.34

MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol (2009) 1.32

Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics (2008) 1.28

Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer (2002) 1.26

Effectiveness of prehospital wireless transmission of electrocardiograms to a cardiologist via hand-held device for patients with acute myocardial infarction (from the Timely Intervention in Myocardial Emergency, NorthEast Experience [TIME-NE]). Am J Cardiol (2006) 1.25

Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res (2007) 1.23

Near-infrared spectroscopy can monitor dynamic cerebral autoregulation in adults. Neurocrit Care (2008) 1.23

EAU guidelines on primary urethral carcinoma. Eur Urol (2013) 1.22

Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int (2012) 1.18

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18

Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int (2010) 1.18

Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol (2005) 1.17

Urine biomarkers in prostate cancer. Nat Rev Urol (2010) 1.17

Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int (2007) 1.16

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology (2012) 1.16

Spinal-cord MRI in multiple sclerosis. Lancet Neurol (2003) 1.15

The patient's experience of being a human subject. J R Soc Med (2008) 1.15

Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Mult Scler (2010) 1.14

The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13

Comparison of early oncologic results of laparoscopic radical prostatectomy by extraperitoneal versus transperitoneal approach. Eur Urol (2004) 1.12

Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int (2008) 1.11

Impact on clinical and cost outcomes of a centralized approach to acute stroke care in London: a comparative effectiveness before and after model. PLoS One (2013) 1.11

Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. BJU Int (2010) 1.10

SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology (2012) 1.10

Positive surgical margins in laparoscopic radical prostatectomy: the impact of apical dissection, bladder neck remodeling and nerve preservation. J Urol (2003) 1.10

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int (2013) 1.10

The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int (2011) 1.08

A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol (2008) 1.07

Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol (2012) 1.07

Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05

Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World J Urol (2006) 1.05

Analysis of complications from 600 retroperitoneoscopic procedures of the upper urinary tract during the last 10 years. World J Urol (2008) 1.04

Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. Eur Urol (2002) 1.03

Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol (2010) 1.03

Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol (2009) 1.02

The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. J Urol (2010) 1.02

PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer (2013) 1.02

Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial. BJU Int (2013) 1.02